Exai Bio snags $67.5m Series A
Exai Bio, a next-generation liquid biopsy company, has secured $67.5 million in Series A financing.
Exai Bio, a next-generation liquid biopsy company, has secured $67.5 million in Series A financing.
Copyright PEI Media
Not for publication, email or dissemination